Literature DB >> 16575876

A genome wide linkage search for breast cancer susceptibility genes.

Paula Smith1, Lesley McGuffog, Douglas F Easton, Graham J Mann, Gulietta M Pupo, Beth Newman, Georgia Chenevix-Trench, Csilla Szabo, Melissa Southey, Hélène Renard, Fabrice Odefrey, Henry Lynch, Dominique Stoppa-Lyonnet, Fergus Couch, John L Hopper, Graham G Giles, Margaret R E McCredie, Saundra Buys, Irene Andrulis, Ruby Senie, David E Goldgar, Rogier Oldenburg, Karin Kroeze-Jansema, Jaennelle Kraan, Hanne Meijers-Heijboer, Jan G M Klijn, Christi van Asperen, Inge van Leeuwen, Hans F A Vasen, Cees J Cornelisse, Peter Devilee, Linda Baskcomb, Sheila Seal, Rita Barfoot, Jon Mangion, Anita Hall, Sarah Edkins, Elizabeth Rapley, Richard Wooster, Jenny Chang-Claude, Diana Eccles, D Gareth Evans, P Andrew Futreal, Katherine L Nathanson, Barbara L Weber, Nazneen Rahman, Michael R Stratton.   

Abstract

Mutations in known breast cancer susceptibility genes account for a minority of the familial aggregation of the disease. To search for further breast cancer susceptibility genes, we performed a combined analysis of four genome-wide linkage screens, which included a total of 149 multiple case breast cancer families. All families included at least three cases of breast cancer diagnosed below age 60 years, at least one of whom had been tested and found not to carry a BRCA1 or BRCA2 mutation. Evidence for linkage was assessed using parametric linkage analysis, assuming both a dominant and a recessive mode of inheritance, and using nonparametric methods. The highest LOD score obtained in any analysis of the combined data was 1.80 under the dominant model, in a region on chromosome 4 close to marker D4S392. Three further LOD scores over 1 were identified in the parametric analyses and two in the nonparametric analyses. A maximum LOD score of 2.40 was found on chromosome arm 2p in families with four or more cases of breast cancer diagnosed below age 50 years. The number of linkage peaks did not differ from the number expected by chance. These results suggest regions that may harbor novel breast cancer susceptibility genes. They also indicate that no single gene is likely to account for a large fraction of the familial aggregation of breast cancer that is not due to mutations in BRCA1 or BRCA2. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16575876      PMCID: PMC2714969          DOI: 10.1002/gcc.20330

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  36 in total

1.  Genome-wide scanning for linkage in Finnish breast cancer families.

Authors:  Pia Huusko; Suh-Hang Hank Juo; Elizabeth Gillanders; Laura Sarantaus; Tommi Kainu; Pia Vahteristo; Minna Allinen; MaryPat Jones; Katrin Rapakko; Hannaleena Eerola; Carol Markey; Paula Vehmanen; Derek Gildea; Diane Freas-Lutz; Carl Blomqvist; Jaakko Leisti; Guillermo Blanco; Ulla Puistola; Jeffrey Trent; Joan Bailey-Wilson; Robert Winqvist; Heli Nevanlinna; Olli-P Kallioniemi
Journal:  Eur J Hum Genet       Date:  2004-02       Impact factor: 4.246

2.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

Authors: 
Journal:  Am J Hum Genet       Date:  2004-04-30       Impact factor: 11.025

3.  Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE.

Authors:  K Lange; D Weeks; M Boehnke
Journal:  Genet Epidemiol       Date:  1988       Impact factor: 2.135

4.  Faster sequential genetic linkage computations.

Authors:  R W Cottingham; R M Idury; A A Schäffer
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

5.  Linkage analysis and family classification under heterogeneity.

Authors:  J Ott
Journal:  Ann Hum Genet       Date:  1983-10       Impact factor: 1.670

6.  A class of tests for linkage using affected pedigree members.

Authors:  A S Whittemore; J Halpern
Journal:  Biometrics       Date:  1994-03       Impact factor: 2.571

7.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

8.  Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8.

Authors:  F Kerangueven; L Essioux; A Dib; T Noguchi; F Allione; J Geneix; M Longy; R Lidereau; F Eisinger; M J Pébusque
Journal:  Oncogene       Date:  1995-03-02       Impact factor: 9.867

9.  Genetic analysis of breast cancer in the cancer and steroid hormone study.

Authors:  E B Claus; N Risch; W D Thompson
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

10.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer.

Authors:  A C Antoniou; P P D Pharoah; P Smith; D F Easton
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more
  47 in total

Review 1.  BRCA and Breast Cancer-Related High-Penetrance Genes.

Authors:  Sang-Ah Han; Sung-Won Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Journey's end: the quest for BRCA-like hereditary breast cancer genes is nearly over.

Authors:  W D Foulkes; P Polak
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

3.  Gelatinase B (-1562C/T) polymorphism in tumor progression and invasion of breast cancer.

Authors:  P Chiranjeevi; K Mrudula Spurthi; N Santhoshi Rani; G Rajesh Kumar; T Mohini Aiyengar; M Saraswati; G Srilatha; G Kishore Kumar; Sudha Sinha; C Sanjeeva Kumari; B Nagarjuna Reddy; S Vishnupriya; H Surekha Rani
Journal:  Tumour Biol       Date:  2013-12-20

4.  Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients.

Authors:  Simona De Summa; Francesca Graziano; Brunella Pilato; Rosamaria Pinto; Katia Danza; Rosanna Lacalamita; Simona Serratì; Domenico Sambiasi; Mario Grassi; Stefania Tommasi
Journal:  Oncol Lett       Date:  2017-08-04       Impact factor: 2.967

5.  Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.

Authors:  Vitaly Balan; Pratima Nangia-Makker; Ann G Schwartz; Young Suk Jung; Larry Tait; Victor Hogan; Tirza Raz; Yi Wang; Zeng Quan Yang; Gen Sheng Wu; Yongjun Guo; Huixiang Li; Judith Abrams; Fergus J Couch; Wilma L Lingle; Ricardo V Lloyd; Stephen P Ethier; Michael A Tainsky; Avraham Raz
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

6.  Genome-wide linkage scan reveals three putative breast-cancer-susceptibility loci.

Authors:  Juan Manuel Rosa-Rosa; Guillermo Pita; Miguel Urioste; Gemma Llort; Joan Brunet; Conxi Lázaro; Ignacio Blanco; Teresa Ramón y Cajal; Orland Díez; Miguel de la Hoya; Trinidad Caldés; Maria-Isabel Tejada; Anna González-Neira; Javier Benítez
Journal:  Am J Hum Genet       Date:  2009-01-15       Impact factor: 11.025

Review 7.  Polygenic susceptibility to breast cancer: current state-of-the-art.

Authors:  Maya Ghoussaini; Paul D P Pharoah
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

8.  SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women.

Authors:  Shimrit Cohen; Yael Laitman; Bella Kaufman; Roni Milgrom; Uri Nir; Eitan Friedman
Journal:  Fam Cancer       Date:  2008-09-27       Impact factor: 2.375

9.  Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.

Authors:  Logan C Walker; Bryony A Thompson; Nic Waddell; Sean M Grimmond; Amanda B Spurdle
Journal:  PLoS Genet       Date:  2010-02-19       Impact factor: 5.917

10.  Is MSH2 a breast cancer susceptibility gene?

Authors:  Ee Ming Wong; Andrea A Tesoriero; Gulietta M Pupo; Margaret R E McCredie; Graham G Giles; John L Hopper; Graham J Mann; David E Goldgar; Melissa C Southey
Journal:  Fam Cancer       Date:  2007-10-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.